PND6 VALUE OF BUDGET IMPACT ANALYSIS BASED ON EPIDEMIOLOGIC DATA: INSIGHTS FROM MULTIPLE SCLEROSIS IN SAO PAULO, BRAZIL  by Ferreira Da Silva, AL et al.
A388 13th Euro Abstracts
PND2
THE INFLUENCE OF PARENTERAL NUTRITION ON THE PLASMA 
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OBJECTIVES: Parenteral nutrition (PN) is used in various clinical situations. 
However, some interactions might occur with drugs that are administered concur-
rently with PN. Therefore, this search reviews the potential interactions of PN with 
therapeutic drugs (mainly antiepileptics), especially in respect to the plasma protein-
binding of the drug. METHODS: The articles related to the topic were identiﬁ ed 
through the Medline and PubMed. Full text of the articles were then traced from the 
Universiti Sains Malaysia (USM) library subscribed databases, including Wiley-Black-
well Library, Cochrane Library, EBSCOHost, OVID, ScienceDirect, SAGE Premier, 
Scopus, SpringerLINK, and Wiley InterScience. The articles from journals not listed 
by USM library were traced through inter library loan. RESULTS: There were interac-
tions between PN and drugs, including antiepileptics. Several guidelines were designed 
for the management of illnesses such as traumatic brain injuries or cancer patients, 
involving the use of PN and antiepileptics. Moreover, many studies demonstrated the 
in vitro and in vivo PN-drugs interactions, especially with antiepileptics. CONCLU-
SIONS: Alteration in the drug-free fraction result from PN-drug (i.e. antiepileptics) 
interactions may necessitate scrupulous reassessment of drug dosages in patients 
receiving these therapies. This reassessment may be particularly imperative in certain 
clinical situations characterized by hypoalbuminemia (e.g., burn patients).
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OBJECTIVES: The aim of this meta-analysis was to evaluate the efﬁ cacy and tolerabil-
ity of IFN β for maintenance of remission in MS. METHODS: Pubmed, Scopus, and 
Cochrane Central Register of Controlled Trials were searched for studies investigated 
efﬁ cacy and/or tolerability of interferon β (IFN β) in MS. Data were collected from 
1966 to 2009 (up to July). RESULTS: Nine randomized placebo controlled clinical 
trials met our criteria and were included. Summary relative risk (RR) for at least one 
relapse including all types of MS and all types of IFN β was 0.86, a signiﬁ cant RR 
(95% CI: 0.76–0.97). Summary RR for at least one relapse in secondary progressive 
MS (SPMS) patients received all types of IFN β was 1.11(95% CI: 0.79–1.55). RR 
for at least one relapse in RRMS patients received all types of IFN β was 0.77(95% 
CI: 0.57–1.05). RR for at least one relapse in SPMS patients received IFN β-1b was 
0.93 (95% CI: 0.75–1.14). RR for at least one relapse in patients with all types of 
MS received IFN β-1a was 0.97 (95% CI: 0.57–1.67) and for IFN β-1b was 0.92 
(95% CI: 0.85–1). The summary RR for discontinuing because of adverse events in 
nine trials was 2.76, a non-signiﬁ cant RR (95% CI: 1.97–3.89, P < 0.0001). The 
summary RR death in three trials was 1.53 (95% CI: 0.45–5.15). RR for suicides or 
suicide attempts in ﬁ ve trials was 0.86 (95% CI: 0.41–1.79). RR for different adverse 
events of all types of IFN β comparing to placebo in all types of MS including ﬂ u-like 
symptoms, injection site reactions, injection site inﬂ ammation, myalgia, leucopenia, 
lymphopenia, increased alanine aminotransferase were signiﬁ cant except for depres-
sion that its RR was non-signiﬁ cant. CONCLUSIONS: It can be concluded that INF 
β’s effectiveness in MS is dependent to administration of different kind of interferon 
β and type of MS. 
NEUROLOGICAL DISORDERS – Cost Studies
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OBJECTIVES: To estimate the annual and 5-year budgetary impact of including 
natalizumab in the Brazilian public health care system drug formulary for the treat-
ment of relapsing remitting multiple sclerosis (MS). METHODS: Brazilian public 
health care system perspective was adopted. The baseline scenario comprised four 
treatment options available in Brazil in the year 2009, and its corresponding market 
shares: 1) interferon beta 1A intramuscular (23%); 2) interferon beta 1A subcutaneous 
(32%); 3) interferon beta 1B (23%); and (4) glatiramer acetate (22%). Data were 
retrieved from the Brazilian health system database. a claims data based approach was 
used to estimate the baseline population size, which was estimated to be 6935 patients. 
In addition to the base-case scenario, three alternative scenarios were created to 
estimate the budgetary impact of including natalizumab to the drug formulary at 3 
possible market shares: 3%, 10% or 22%. Costs for currently available treatments 
comprised average purchase prices paid by the Brazilian government in 2009. The 
adopted natalizumab dose cost was R$,652 (c1660), obtained from public data issued 
by the Brazilian’s regulatory health agency (ANVISA). Costs were adjusted for 4% 
annual inﬂ ation. No discounts were considered. Sensitivity analysis was performed. 
RESULTS: Base-case costs for treatment of MS within a 5-year period were 
R$1280,698,041 (c582,135,473). Relative to this value, at 3% market share, the 
inclusion of natalizumab produced a 6% (R$78,858,437/c35,844,744) increase in 
expenditures. At 10% market share, the corresponding expenditures increased 9% 
(R$108,902,983/c49,501,356). At 22% market share, there was an increase of 13% 
in total costs with MS treatment (R$161,903,806/c73,592,639). CONCLUSIONS: 
Entry of natalizumab into the market is likely to result in a signiﬁ cant increase in MS 
treatment costs for the Brazilian health care system. However, this must be weighted 
against the need for new treatment options as well as potential savings from better 
disease control rates.
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OBJECTIVES: Lennox-Gastaut Syndrome (LGS) is an epileptic encephalopathy char-
acterized by intractable seizures of many types. LGS has its onset in early childhood, 
and often persists into adulthood. It is estimated that the prevalence of LGS among 
children and adults with epilepsy is 6.5% and 1.5%, respectively. This budget impact 
model was developed to help US payers make informed decisions regarding the addi-
tion of ruﬁ namide for the management of LGS. To analyze overall budget impact of 
changing ruﬁ namide from tier 3 to tier 2 status for a large U.S. payer. METHODS: 
The budget impact model was constructed based upon the indicated population for 
ruﬁ namide, which is children 4 years and older and adults (18+) requiring adjunctive 
treatment of seizures associated with LGS. The model follows patients over three years 
and estimates the direct health care costs associated with LGS treatment before and 
after the introduction of ruﬁ namide. The three main categories of data inputs inform-
ing the model include: plan population inputs, treated prevalence inputs, and treat-
ment and cost inputs. The base-case model results are based on data derived from 
published literature, publicly available data sources, or assumptions. The results are 
presented as follows: total costs over 3 years, cost per member per year (PMPY), cost 
per treated member per year (PTMPY), cost per member per month (PMPM), and 
cost per treated member per month (PTMPM). RESULTS: Assuming a one million 
member plan and a discount rate of 3% shifting ruﬁ namide from tier 3 to tier 2 
resulted in $1,001 in additional total costs over 3 years. This translates to a change 
in a PTMPY of $1.00 and a PTMPM of $0.13. PMPY and PMPM were not notably 
affected. CONCLUSIONS: Based on this analysis changing ruﬁ namide from tier 3 to 
tier 2 does not exhibit a signiﬁ cant cost increase.
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BACKGROUND: Despite its relatively low prevalence in Brazil, multiple sclerosis (MS) 
is responsible for signiﬁ cant health care expenditures for the public health care system. 
OBJECTIVES: To compare actual MS treatment expenditures and expected expenditures 
based on an epidemiological projection. METHODS: We retrieved actual treated preva-
lence and treatment costs from Brazil’s public health system database for the city of Sao 
Paulo, in 2009. Then, current prevalence of MS for the city of Sao Paulo was estimated 
based on the best epidemiological evidence available, a prevalence study conducted in 
1997, which reported a prevalence of 15/100,000 inhabitants. Data were analyzed com-
paring actual and potential expenditure related to drug treatments, assuming that 85% 
of prevalent cases comprised the relapsing form of MS. RESULTS: We retrieved the total 
number of doses for each one of the available treatment options for MS in the city of São 
Paulo for the year 2009 (interferon beta-1A, interferon beta-1B and glatiramer acetate). 
Considering the expected number of doses required to treat one patient for one year with 
each treatment option, we estimated the number of patients covered within one year of 
treatment to be 1,319 patients. This corresponds to an estimated treated prevalence of 
11.9 cases per 100,000 inhabitants, considering the estimated population for the year 
2009 (11,037,593 inhabitants). Actual costs incurred for the city of Sao Paulo in 2009 
with the treatment of MS were R$40,993,666/c18,633,484. Assuming a prevalence of 
15/100,000 inhabitants, 1,666 cases of MS would be expected in the city, of which 1,416 
would be relapsing MS. Their treatment would require R$43,811,800/c19,914,454. 
CONCLUSIONS: There are marginal differences between treated and expected prevalence 
of relapsing MS in the city of Sao Paulo. This indicates that local programs for MS 
diagnosis and treatment are successful. Likewise, current budget impacted analyses based 
on epidemiologic information seems accurate.  
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OBJECTIVES: Multiple sclerosis (MS) is a chronic incurable disease with a progressive 
course. Studies have demonstrated that disease progression can be slowed by treatment 
with disease modifying therapies (DMTs). Poor DMT adherence is associated with a 
